Plenary

The Future of Psychedelic Therapeutics in C-L Psychiatry: Practical, Ethical, and ‎Clinical Perspectives

Plenary: The Future of Psychedelic Therapeutics in C-L Psychiatry: Practical, Ethical, and ‎Clinical Perspectives

Saturday, November 9, 2024

10:30 AM – 11:30 AM EST

Location: James L. Knight Center

Speaker(s)

Jacob Appel, MD JD DFAPA

Professor
Icahn School of Medicine at Mount Sinai
New York, New York

Handouts
Jacob Appel, MD JD DFAPA

Professor
Icahn School of Medicine at Mount Sinai
New York, New York

Handouts
RS

Roxanne Sholevar, MD

Staff Psychiatrist
Dana-Farber Cancer Institute
Boston, Massachusetts
RS

Roxanne Sholevar, MD

Staff Psychiatrist
Dana-Farber Cancer Institute
Boston, Massachusetts
J.J. Rasimas, PhD, MD, FAACT, FACLP, FACMT, FACPsych

Medical Director, C-L Psychiatry Service & Fellowship
Hennepin County Medical Center
Minneapolis, Minnesota
J.J. Rasimas, PhD, MD, FAACT, FACLP, FACMT, FACPsych

Medical Director, C-L Psychiatry Service & Fellowship
Hennepin County Medical Center
Minneapolis, Minnesota

Moderator(s)

JS

John L. Shuster, Jr., MD, FACLP

Director
Clinical Resource Hub, VA MidSouth Healthcare Network
Nashville, Tennessee
JS

John L. Shuster, Jr., MD, FACLP

Director
Clinical Resource Hub, VA MidSouth Healthcare Network
Nashville, Tennessee

Saturday’s plenary session deals with psychedelics, an evolving drug class with an ‎interesting and controversial history, now enjoying a resurgence in clinical interest and ‎advocacy for wider applications in psychiatric care. Panelists will address the toxicology of ‎these agents, studies of their clinical application, and ethical considerations of ‎psychedelic therapeutics in the context of the current evidence base. ‎

Learning Objectives:

• Participants will consider different varieties of psychedelic compounds with attention to the ‎complexity involved in ascertaining potential medicinal and medical benefits in balance with ‎immediate and longitudinal toxicologic risks.‎
• Participants will appreciate potential therapeutic opportunities and risks of psychedelic-assisted ‎therapies in the consultation-liaison psychiatry setting, with a particular emphasis on ‎psychedelic therapies in patients with serious medical illness. ‎
• Participants will learn how to navigate emerging legal and ethical issues related to the use of ‎psychedelics in the clinical setting including those related to standards of care, informed ‎consent, conflicts between federal and state law, the right to try, and liability insurance coverage‎